The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain has proposed a grading system for the presence of neuropathic pain (NeP) using the following categories: no NeP, possible, probable, or definite NeP. To further evaluate this system, we investigated patients with neck/upper limb pain with a suspected nerve lesion, to explore: (i) the clinical application of this grading system; (ii) the suitability of 2 NeP questionnaires (Leeds Assessment of Neuropathic Symptoms and Signs pain scale [LANSS] and the painDETECT questionnaire [PD-Q]) in identifying NeP in this patient cohort; and (iii) the level of agreement in identifying NeP between the NeuPSIG classification system and 2 NeP questionnaires. Patients (n = 152; age 52 ± 12 years; 53% male) completed the PD-Q and LANSS questionnaire and underwent a comprehensive clinical examination. The NeuPSIG grading system proved feasible for application in this patient cohort, although it required considerable time and expertise. Both questionnaires failed to identify a large number of patients with clinically classified definite NeP (LANSS sensitivity 22%, specificity 88%; PD-Q sensitivity 64%, specificity 62%). These lowered sensitivity scores contrast with those from the original PD-Q and LANSS validation studies and may reflect differences in the clinical characteristics of the study populations. The diagnostic accuracy of LANSS and PD-Q for the identification of NeP in patients with neck/upper limb pain appears limited. Ó
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Introduction
Neuropathic pain (NeP), defined as ''pain arising as a direct consequence of a lesion or disease affecting the somatosensory sys- . This classification approach is based on a stepwise process that requires a history-derived working hypothesis (based on pain distribution and history suggesting a relevant lesion), and confirmatory evidence from a neurological examination and diagnostic tests. The application of this grading system has been demonstrated in some case studies [31, 35] and was consequently used in various pain populations [32,39,43], but not in patients with neck/upper limb pain.
Questionnaires are used as screening tools to aid identification of suspected NeP [10, 22] and are recommended for clinical use, including by nonspecialists [34] . The Leeds Assessment of Neuropathic Symptoms and Signs pain scale (LANSS) [9] discriminates between patients with or without pain of predominantly neuropathic origin, and is applied in an interview format. The LANSS contains 5 sensory descriptor items and 2 clinical examination items. LANSS was developed in 60 patients with distinct clinical diagnostic categories of NeP and non-NeP, and demonstrated a sensitivity of 83% and specificity of 87%, and was further validated in 40 patients (sensitivity 85%, specificity of 80%) [9] .
